MDEA
Methylenedioxyethylamphetamine (MDEA), also known as MDE, is a psychoactive drug and entactogen of the phenethylamine and amphetamine chemical classes. It is known for its empathogenic effects similar to those of MDMA (ecstasy), though it is considered to be less potent in terms of both its stimulant and psychedelic effects.
MDEA acts primarily by increasing the activity of three neurotransmitters: serotonin, dopamine, and norepinephrine. It achieves this by inhibiting their reuptake and release from the neurons in the brain. The increase in serotonin is thought to be responsible for the mood-lifting and empathogenic effects of MDEA, while the increase in dopamine and norepinephrine contributes to its stimulant properties and feelings of euphoria.
History
MDEA first gained popularity in the 1980s as a recreational drug among participants in the rave and electronic dance music scenes. Its use has been associated with the so-called "second summer of love" in the late 1980s, a period characterized by the rise of rave culture and electronic dance music.
Effects
The effects of MDEA can vary depending on the dose, the purity of the drug, and the individual's physiology and state of mind. Common effects include feelings of euphoria, increased energy, enhanced sensory perception, and increased empathy and sociability. However, MDEA can also cause a range of adverse effects, including nausea, dehydration, hyperthermia, bruxism (teeth grinding), and in rare cases, severe health complications such as serotonin syndrome.
Legal Status
The legal status of MDEA varies by country, but it has been classified as a controlled substance in many parts of the world, including the United States, where it is listed as a Schedule I drug under the Controlled Substances Act. This classification indicates that it is considered to have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD